Plasmaferese : veilig bij een goede indicatiestelling en kennis van de complicaties [Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications]

Détails

ID Serval
serval:BIB_DB84932BD5C9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Plasmaferese : veilig bij een goede indicatiestelling en kennis van de complicaties [Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications]
Périodique
Nederlands Tijdschrift voor Geneeskunde
Auteur(s)
Pruijm M.T., Vogt B., Cherpillod A., Burnier M.
ISSN
0028-2162
Statut éditorial
Publié
Date de publication
2008
Volume
152
Numéro
42
Pages
2261-2266
Langue
danois
Résumé
Plasmapheresis is an extracorporeal technique used to remove pathogenic macromolecules from the circulation, particularly autoantibodies. This is illustrated in 2 female patients. The first patient, aged 61 years, was treated successfully with non-selective plasmapheresis for acute humoral rejection shortly after receiving a renal allograft. In the second patient, aged 82 years, plasmapheresis for refractory myasthenia gravis had to be stopped because of bradycardia and hypotension during the procedure. She was treated successfully with immunoglobulins. Plasmapheresis is used to treat neurological, renal, haematological and systemic disorders. In nonselective plasmapheresis, the plasma is replaced with saline and albumin or donor plasma. In selective plasmapheresis a highly selective filter is used to remove a specific, pathogenic macromolecule. Adverse effects of the treatment include disturbances of the acid-base equilibrium or the coagulation, and allergic reactions. Most of these complications, however, can nowadays be avoided.
Mots-clé
Aged, 80 and over, Antibodies/blood, Antibody Formation/physiology, Female, Graft Rejection/immunology, Graft Rejection/therapy, Homeostasis, Humans, Immunoglobulins, Intravenous, Kidney Transplantation/adverse effects, Middle Aged, Myasthenia Gravis/therapy, Plasmapheresis/methods, Risk Factors, Treatment Outcome
Pubmed
Création de la notice
29/01/2009 22:14
Dernière modification de la notice
20/08/2019 16:00
Données d'usage